SCLERODERMA 101. Maureen D. Mayes, MD, MPH Professor of Medicine University of Texas - Houston

Size: px
Start display at page:

Download "SCLERODERMA 101. Maureen D. Mayes, MD, MPH Professor of Medicine University of Texas - Houston"

Transcription

1 SCLERODERMA 101 Maureen D. Mayes, MD, MPH Professor of Medicine University of Texas - Houston

2 TYPES OF SCLERODERMA Localized versus Systemic

3 Two Kinds of Scleroderma Localized Scleroderma Morphea Linear Scleroderma En coupe de sabre Combinations Systemic Scleroderma (SSc, Systemic sclerosis) Limited cutaneous (lcssc) Diffuse cutaneous (dcssc)

4 MORPHEA

5 LOCALIZED SCLERODERMA (not Systemic) Involves the skin and underlying tissue usually does not involve internal organs Linear Scleroderma a line of thickened skin down one leg or arm Scleroderma en coup de sabre (cut of the saber) a line of thickened skin involving the scalp, forehead and the face Morphea: Patches of thickened skin anywhere on the body Can be a single patch or multiple patches

6 LOCALIZED SCLERODERMA (not Systemic) Involves the skin and underlying tissue usually does not involve internal organs Linear Scleroderma a line of thickened skin down one leg or arm Scleroderma en coup de sabre (cut of the saber) a line of thickened skin involving the scalp, forehead and the face Morphea: Patches of thickened skin anywhere on the body Can be a single patch or multiple patches

7 LOCALIZED SCLERODERMA (not Systemic) Involves the skin and underlying tissue usually does not involve internal organs Linear Scleroderma a line of thickened skin down one leg or arm Scleroderma en coup de sabre (cut of the saber) a line of thickened skin involving the scalp, forehead and the face Morphea: Patches of thickened skin anywhere on the body Can be a single patch or multiple patches

8 LOCALIZED SCLERODERMA (not Systemic) Involves the skin and underlying tissue usually does not involve internal organs Linear Scleroderma a line of thickened skin down one leg or arm Scleroderma en coup de sabre (cut of the saber) a line of thickened skin involving the scalp, forehead and the face Morphea: Patches of thickened skin anywhere on the body Can be a single patch or multiple patches

9 Systemic Sclerosis (SSc) Limited versus Diffuse Disease

10 RAYNAUD S PHENOMENON: Pallor Phase

11 RAYNAUD S PHENOMENON: Pallor and Cyanosis

12 TWO FACES OF Systemic SCLERODERMA (SSc)

13 Diffuse Scleroderma

14 Diffuse Cutaneous SSc Skin thickening upper arms, thighs, trunk in addition to hands and distal extremities 40% of SSc cases More likely to be associated with progressive lung fibrosis, and/or scleroderma renal crisis, and/or significant GI disease, and/or cardiac disease Each patient is different

15 Telangiectasia of Limited SSc

16 Limited Cutaneous SSc Skin thickening confined to distal extremities (both forms can involve the face) Usually has more mild internal organ disease Associated with anticentromere antibodies Sometimes called CREST for Calcinosis, Raynaud s, Esophageal Dysmotility, Sclerodactyly, and Telangiectasias.

17 ORGAN INVOLVEMENT in SSc Raynaud s phenomenon and digital ulcers Pulmonary fibrosis Pulmonary hypertension Cardiac involvement Gastroesophageal (GI) problems Joint problems Other

18 ORGAN INVOLVEMENT in SSc Raynaud s phenomenon and digital ulcers Pulmonary fibrosis Pulmonary hypertension Cardiac involvement Gastroesophageal (GI) problems Joint problems Other

19 ORGAN INVOLVEMENT in SSc Raynaud s phenomenon and digital ulcers Pulmonary fibrosis Pulmonary hypertension Cardiac involvement Gastroesophageal (GI) problems Joint problems Other

20 ORGAN INVOLVEMENT in SSc Raynaud s phenomenon and digital ulcers Pulmonary fibrosis Pulmonary hypertension Cardiac involvement Gastroesophageal (GI) problems Joint problems Other

21 ORGAN INVOLVEMENT in SSc Raynaud s phenomenon and digital ulcers Pulmonary fibrosis Pulmonary hypertension Cardiac involvement Gastroesophageal (GI) problems Joint problems Other

22 ORGAN INVOLVEMENT in SSc Raynaud s phenomenon and digital ulcers Pulmonary fibrosis Pulmonary hypertension Cardiac involvement Gastroesophageal (GI) problems Joint problems Other

23 The Causes of SSc What we know & What we don t know

24 The Causes of SSc What we know: Some genes increase susceptibility but are not enough The Immune system is activated Small blood vessels start to narrow Deep skin cells (fibroblasts) increase collagen production What we don t know: The external trigger that starts the process The key points in the process that can be interrupted to stop the disease

25 The Causes of SSc What we know: Some genes increase susceptibility but are not enough The Immune system is activated Small blood vessels start to narrow Deep skin cells (fibroblasts) increase collagen production What we don t know: The external trigger that starts the process The key points in the process that can be interrupted to stop the disease

26 The Causes of SSc What we know: Some genes increase susceptibility but are not enough The Immune system is activated Small blood vessels start to narrow Deep skin cells (fibroblasts) increase collagen production What we don t know: The external trigger that starts the process The key points in the process that can be interrupted to stop the disease

27 The Causes of SSc What we know: Some genes increase susceptibility but are not enough The Immune system is activated Small blood vessels start to narrow Deep skin cells (fibroblasts) increase collagen production What we don t know: The external trigger that starts the process The key points in the process that can be interrupted to stop the disease

28 The Causes of SSc What we know: Some genes increase susceptibility but are not enough The Immune system is activated Small blood vessels start to narrow Deep skin cells (fibroblasts) increase collagen production What we don t know: The external trigger that starts the process The key points in the process that can be interrupted to stop the disease

29 The Causes of SSc What we know: Some genes increase susceptibility but are not enough The Immune system is activated Small blood vessels start to narrow Deep skin cells (fibroblasts) increase collagen production What we don t know: The external trigger that starts the process The key points in the process that can be interrupted to stop the disease

30 THE TREATMENT OF Scleroderma

31 Treatment of MORPHEA

32 The Treatment of Localized Scleroderma Is it active? Intralesional steroids Methotrexate Other immunosuppressive medications Risk versus benefit ratio

33 RISKS > BENEFITS

34 RISKS = BENEFITS

35 RISKS << BENEFITS

36 TREATMENT OF Systemic Scleroderma Therapy depends on the organs involved

37 What are the treatment goals? Skin decrease thickening (fibrosis) Tendons and joints decrease inflammation Raynaud s phenomenon improve circulation Digital ulcers improve circulation Pulmonary fibrosis decrease scar tissue (fibrosis) Pulmonary hypertension improve circulation Gastrointestinal involvement esophagus, stomach, bowel decrease acid, improve motion, treat bacterial overgrowth Kidney involvement control blood pressure

38 What are the treatment goals? Skin decrease thickening (fibrosis) Tendons and joints decrease inflammation Raynaud s phenomenon improve circulation Digital ulcers improve circulation Pulmonary fibrosis decrease scar tissue (fibrosis) Pulmonary hypertension improve circulation Gastrointestinal involvement esophagus, stomach, bowel decrease acid, improve motion, treat bacterial overgrowth Kidney involvement control blood pressure

39 What are the treatment goals? Skin decrease thickening (fibrosis) Tendons and joints decrease inflammation Raynaud s phenomenon improve circulation Digital ulcers improve circulation Pulmonary fibrosis decrease scar tissue (fibrosis) Pulmonary hypertension improve circulation Gastrointestinal involvement esophagus, stomach, bowel decrease acid, improve motion, treat bacterial overgrowth Kidney involvement control blood pressure

40 What are the treatment goals? Skin decrease thickening (fibrosis) Tendons and joints decrease inflammation Raynaud s phenomenon improve circulation Digital ulcers improve circulation Pulmonary fibrosis decrease scar tissue (fibrosis) Pulmonary hypertension improve circulation Gastrointestinal involvement esophagus, stomach, bowel decrease acid, improve motion, treat bacterial overgrowth Kidney involvement control blood pressure

41 All SSc Patients are Different Each person is likely to have a different combination of problems So each person may be on a different combination of medications Some may be on little or no medicine Others are on tons of medicine

42 WHAT YOU CAN DO Learn about the disease Keep track of your test results Ask questions Participate in trials

43 QUESTIONS, CONCERNS, ISSUES

Scleroderma Facts. The Scleroderma Foundation is here to help!

Scleroderma Facts. The Scleroderma Foundation is here to help! Scleroderma Facts Scleroderma is an autoimmune disease whose symptoms typically include some or all of the following: sensitivity to cold in extremities, thickening of the skin, shortness of breath, difficulty

More information

SCLERODERMA: An Update. What You Need To Know

SCLERODERMA: An Update. What You Need To Know SCLERODERMA: An Update What You Need To Know Pre Test Question #1 The onset of systemic sclerosis is typically: A. In the 1st decade of life B. Between the 4th and 6th decade C. Equal in all age groups

More information

Scleroderma. Nomenclature Synonyms. Scleroderma. Progressive Systemic Sclerosis. Systemic Sclerosis. Edward Dwyer, M.D. Division of Rheumatology

Scleroderma. Nomenclature Synonyms. Scleroderma. Progressive Systemic Sclerosis. Systemic Sclerosis. Edward Dwyer, M.D. Division of Rheumatology Scleroderma Edward Dwyer, M.D. Division of Rheumatology Nomenclature Synonyms Scleroderma Progressive Systemic Sclerosis Systemic Sclerosis Scleroderma 1 Scleroderma Chronic systemic autoimmune disease

More information

Scleroderma. Nomenclature Synonyms. Scleroderma. Progressive Systemic Sclerosis. Systemic Sclerosis. Limited vs. Diffuse Scleroderma.

Scleroderma. Nomenclature Synonyms. Scleroderma. Progressive Systemic Sclerosis. Systemic Sclerosis. Limited vs. Diffuse Scleroderma. Scleroderma Edward Dwyer, M.D. Division of Rheumatology Nomenclature Synonyms Scleroderma Progressive Systemic Sclerosis Systemic Sclerosis Scleroderma Chronic systemic autoimmune disease characterized

More information

Systemic sclerosis (SSC)

Systemic sclerosis (SSC) Systemic sclerosis (SSC) -Is a multi system autoimmune disease, characterized by fibrosis of the skin and variable pattern of other visceral -SSC: Is a relatively UN common disease -Prevalence in U S A

More information

SCLERODERMA. Scleroderma update. No disclosures or conflicts. Leslie Kahl, M.D. April 10, 2015

SCLERODERMA. Scleroderma update. No disclosures or conflicts. Leslie Kahl, M.D. April 10, 2015 Scleroderma update Leslie Kahl, M.D. April 10, 2015 No disclosures or conflicts KT is a 45 year old woman who developed puffiness in her fingers 1/2013 and carpal tunnel syndrome and arthralgias 3/2013.

More information

Scleroderma FAQ. About this Document

Scleroderma FAQ. About this Document Scleroderma FAQ About this Document The Scleroderma FAQ * is a comprehensive document that covers systemic scleroderma diagnosis and treatment. All information contained in the FAQ is based on current

More information

Systemic sclerosis and GI involvement

Systemic sclerosis and GI involvement Systemic sclerosis and GI involvement Dr Maggie Larché, MRCP(UK), PhD Associate Professor, Division of Rheumatology, McMaster University St Joseph s Hospital Scleroderma CME, St Joseph s Hospital, September

More information

Academic Affiliate Fellowship Practice Exam: 2018

Academic Affiliate Fellowship Practice Exam: 2018 Academic Affiliate Fellowship Practice Exam: 2018 Current History: A patient presents to your practice complaining of a tight feeling in her perioral tissue area. She is unable to open her mouth fully

More information

What will we discuss today?

What will we discuss today? Autoimmune diseases What will we discuss today? Introduction to autoimmune diseases Some examples Introduction to autoimmune diseases Chronic Sometimes relapsing Progressive damage Epitope spreading more

More information

associated conditions a closer look at connective tissue disease and PAH

associated conditions a closer look at connective tissue disease and PAH associated conditions a closer look at connective tissue disease and PAH The link between connective tissue disease and PAH Those living with a connective tissue disease (CTD) have an increased risk of

More information

BSR and BHPR guideline for the treatment of systemic sclerosis

BSR and BHPR guideline for the treatment of systemic sclerosis BSR and BHPR guideline for the treatment of systemic sclerosis Christopher P. Denton, Michael Hughes, Nataliya Gak, Josephine Vila, Maya Buch, Kuntal Chakravarty, Kim Fligelstone, Luke L Gompels, Bridget

More information

Chapter 1 Introduction

Chapter 1 Introduction Chapter 1 Introduction Chapter 1-1 Chapter Highlights 1. This Manual is for You 2. What is Scleroderma? 3. Who gets Scleroderma? 4. What are the Early Symptoms of Scleroderma? 5. Is All Scleroderma the

More information

Understanding and Managing. Scleroderma. Maureen D. Mayes, M.D., M.P.H.

Understanding and Managing. Scleroderma. Maureen D. Mayes, M.D., M.P.H. Understanding and Managing Scleroderma Maureen D. Mayes, M.D., M.P.H. Understanding and Managing Scleroderma Maureen D. Mayes, M.D., M.P.H. Understanding and Managing Scleroderma This booklet is intended

More information

https://www.printo.it/pediatric-rheumatology/gb/intro Scleroderma Version of 2016 1. WHAT IS SCLERODERMA 1.1 What is it? The name scleroderma is derived from Greek and can be translated as "hard skin".

More information

Autoimmune diseases. SLIDE 3: Introduction to autoimmune diseases Chronic

Autoimmune diseases. SLIDE 3: Introduction to autoimmune diseases Chronic SLIDE 3: Introduction to autoimmune diseases Chronic Autoimmune diseases Sometimes relapsing : and remitting. which means that they present as attacks Progressive damage Epitope spreading more and more

More information

DocSpot what patients want to know

DocSpot what patients want to know DocSpot what patients want to know Professor Chris Denton Royal Free Hospital London, UK Madrid, February 2012 Copyright 2011 Raynaud's & Scleroderma Association. Charity Reg. No. 326306 DocSpot Live!

More information

Having a stem cell transplant for scleroderma a patient and doctor perspective

Having a stem cell transplant for scleroderma a patient and doctor perspective Having a stem cell transplant for scleroderma a patient and doctor perspective Professor Chris Denton, On behalf of an excellent team across UCLPartners Royal Free Hospital and University College London,

More information

Myositis and Your Lungs

Myositis and Your Lungs Myositis and Your Lungs 2013 TMA Annual Patient Meeting Louisville, Kentucky Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Myositis Heterogeneous group of autoimmune syndromes

More information

B. Scleroderma. 6. Nodular cutaneous lupus mucinosis. 7. Bullous lupus erythematosus. 1. Systemic sclerosis (SSc)

B. Scleroderma. 6. Nodular cutaneous lupus mucinosis. 7. Bullous lupus erythematosus. 1. Systemic sclerosis (SSc) Go Back to the Top To Order, Visit the Purchasing Page for Details antiodies. Symptomatic therapies for the eruptions and the systemic symptoms are the main treatments. A pacemaker may e implanted in patients

More information

Scleroderma and PAH Overview. PH Resource Network Martha Kingman, FNP C UTSW Medical Center at Dallas

Scleroderma and PAH Overview. PH Resource Network Martha Kingman, FNP C UTSW Medical Center at Dallas Scleroderma and PAH Overview PH Resource Network 2007 Martha Kingman, FNP C UTSW Medical Center at Dallas Scleroderma and PAH Outline: Lung involvement in scleroderma Evaluation of the scleroderma patient

More information

For Your Information. This booklet is not copyrighted. Readers are encouraged to duplicate and distribute as many copies as needed.

For Your Information. This booklet is not copyrighted. Readers are encouraged to duplicate and distribute as many copies as needed. H A N D O U T O N H E A L T H Scleroderma U.S. Department of Health and Human Services National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases For Your Information

More information

CASE STUDY. Improving the Patient Flow of Scleroderma Patients at Chapel Allerton Hospital. Client: Diagnostic Evidence Co-operative (DEC) Leeds

CASE STUDY. Improving the Patient Flow of Scleroderma Patients at Chapel Allerton Hospital. Client: Diagnostic Evidence Co-operative (DEC) Leeds CSE STUDY Improving the Patient Flow of Scleroderma Patients at Chapel llerton Hospital Client: Diagnostic Evidence Co-operative (DEC) Leeds 1 NETIMIS Overview Chapel llerton Hospital is a leader in the

More information

Caring for the Patient With Limited Systemic Scleroderma

Caring for the Patient With Limited Systemic Scleroderma Caring for the Patient With Limited Systemic Scleroderma 2.0 ANCC Contact Hours Kelly Denise Lachner Systemic scleroderma (systemic sclerosis) is a rare, autoimmune, collagen-vascular disease of unknown

More information

A Comparison Between Anti-Th/To and Anticentromere Antibody Positive Systemic Sclerosis Patients With Limited Cutaneous Involvement

A Comparison Between Anti-Th/To and Anticentromere Antibody Positive Systemic Sclerosis Patients With Limited Cutaneous Involvement ARTHRITIS & RHEUMATISM Vol. 48, No. 1, January 2003, pp 203 209 DOI 10.1002/art.10760 2003, American College of Rheumatology A Comparison Between and Anticentromere Antibody Positive Systemic Sclerosis

More information

Peripheral (digital) vasculopathy in systemic. sclerosis. Ariane Herrick

Peripheral (digital) vasculopathy in systemic. sclerosis. Ariane Herrick Peripheral (digital) vasculopathy in systemic sclerosis Ariane Herrick Raynaud s phenomenon VASOPASM DEOXYGENATION REPERFUSION Main causes of RP Primary (idiopathic) Connective tissue diseases, including

More information

SCLERODERMA EPIDEMIOLOGY

SCLERODERMA EPIDEMIOLOGY 1 SCLERODERMA Scleroderma is an autoimmune disorder of unknown etiology, characterized by fibrosis and microvascular injury in affected organs. The hallmark of the disease is thickening and tightness of

More information

Measures of Systemic Sclerosis (Scleroderma)

Measures of Systemic Sclerosis (Scleroderma) Arthritis Care & Research Vol. 63, No. S11, November 2011, pp S98 S111 DOI 10.1002/acr.20598 2011, American College of Rheumatology MEASURES OF PATHOLOGY AND SYMPTOMS Measures of Systemic Sclerosis (Scleroderma)

More information

Understanding & Managing Scleroderma

Understanding & Managing Scleroderma Understanding & Managing Scleroderma UK Registered Charity Number 286736 Number 286736 Printing of this booklet was supported by grants from Actelion Pharmaceuticals UK and Encysive Pharmaceuticals Understanding

More information

Scleroderma What is Scleroderma? What Causes Scleroderma? Who gets Scleroderma? What are the symptoms of Scleroderma? - 1 -

Scleroderma What is Scleroderma? What Causes Scleroderma? Who gets Scleroderma? What are the symptoms of Scleroderma? - 1 - What is Scleroderma? Scleroderma means "hard skin". It is a disease of vascular and connective tissue where the skin and many other parts of the body can become thick and hard. There are two kinds of Scleroderma:

More information

Juvenile Scleroderma

Juvenile Scleroderma Juvenile Scleroderma INTRODUCTION Every parent will experience a moment of panic when told their child has scleroderma. Often they hear little else the doctor has to say. A quick trip to the Internet may

More information

Guide for New and Future Patients

Guide for New and Future Patients Guide for New and Future Patients About this Guide This Guide for New and Future Patients is a companion document to the Scleroderma FAQ TM, also available through the Scleroderma Education Project website:

More information

Citation The Journal of dermatology, 37(1), available at

Citation The Journal of dermatology, 37(1), available at NAOSITE: Nagasaki University's Ac Title Author(s) Case of localized scleroderma assoc Muroi, Eiji; Ogawa, Fumihide; Yamao Sato, Shinichi Citation The Journal of dermatology, 37(1), Issue Date 2010-01 URL

More information

Update in Systemic Sclerosis! Lauren Kim MD! NW Rheumatology Associates

Update in Systemic Sclerosis! Lauren Kim MD! NW Rheumatology Associates Update in Systemic Sclerosis! Lauren Kim MD! NW Rheumatology Associates Review Systemic sclerosis affects approximately 75,000 to 100,000 people in the U.S. and has the highest mortality rate of any autoimmune

More information

A Patient s Guide to Understanding Pulmonary Arterial Hypertension in Systemic Sclerosis

A Patient s Guide to Understanding Pulmonary Arterial Hypertension in Systemic Sclerosis A Patient s Guide to Understanding Pulmonary Arterial Hypertension in Systemic Sclerosis Compared with the general population, patients with systemic sclerosis (also known as scleroderma) have a higher

More information

Reporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation

Reporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation Reporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation Marcelo C. Pasquini, MD, MSc HVD05_1.ppt Outline Review of autoimmune diseases (AID). Role of transplantation for AID Data collection:

More information

Predictors of Isolated Pulmonary Hypertension in Patients With Systemic Sclerosis and Limited Cutaneous Involvement

Predictors of Isolated Pulmonary Hypertension in Patients With Systemic Sclerosis and Limited Cutaneous Involvement ARTHRITIS & RHEUMATISM Vol. 48, No. 2, February 2003, pp 516 522 DOI 10.1002/art.10775 2003, American College of Rheumatology Predictors of Isolated Pulmonary Hypertension in Patients With Systemic Sclerosis

More information

10 pearls in scleroderma for the family practitioner

10 pearls in scleroderma for the family practitioner 10 pearls in scleroderma for the family practitioner Dr Maggie Larche, MRCP(UK), PhD Associate Professor, Division of Rheumatology, McMaster University St Joseph s Hospital Family Medicine Rounds, St Joseph

More information

The First Year: Scleroderma: An Essential Guide For The Newly Diagnosed By Karen Gottesman, Daniel E. Furst

The First Year: Scleroderma: An Essential Guide For The Newly Diagnosed By Karen Gottesman, Daniel E. Furst The First Year: Scleroderma: An Essential Guide For The Newly Diagnosed By Karen Gottesman, Daniel E. Furst Member - The Scleroderma Patient-centered Intervention Network - Author of The First Year: Scleroderma

More information

RHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center

RHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center RHEUMATOLOGY OVERVIEW Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center What is Rheumatology? Medical science devoted to the rheumatic diseases

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Caglayan E, Axmann S, Hellmich M, Moinzadeh P, Rosenkranz S. Vardenafil for the treatment of Raynaud phenomenon: a randomized, double-blind, placebocontrolled crossover study.

More information

SCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW

SCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW SCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW Lung disease can be a serious complication of scleroderma. The two most common types of lung disease in patients with scleroderma are interstitial

More information

different phenotypes

different phenotypes Pulmonary hypertension in scleroderma: different phenotypes UMR 995 Pr David LAUNAY, MD, PhD launayd@gmail.com Service de Médecine Interne. Unité d'immunologie Clinique CNRMR Maladies Systémiques et Autoimmunes

More information

Methodology used to develop new ACR-EULAR criteria. Disclosures. Objectives Guiding principles underlying methodology

Methodology used to develop new ACR-EULAR criteria. Disclosures. Objectives Guiding principles underlying methodology Methodology used to develop new ACR-EULAR criteria Sindhu Johnson MD PhD Toronto Scleroderma Program University of Toronto Co-convenors Janet Pope Frank van den Hoogen Members Jaap Fransen Sindhu Johnson

More information

Understanding and Managing Scleroderma

Understanding and Managing Scleroderma Understanding and Managing Scleroderma FIRST SCLERODERMA NEW ZEALAND EDITION 2016 Understanding And Managing Scleroderma First Scleroderma New Zealand Edition 2016 Acknowledgement An acknowledgement of

More information

Scleroderma. Chronic multisystemic disease characterized by vasculopathy, variable degree of inflammation, and fibrosis

Scleroderma. Chronic multisystemic disease characterized by vasculopathy, variable degree of inflammation, and fibrosis Scleroderma Chronic multisystemic disease characterized by vasculopathy, variable degree of inflammation, and fibrosis Incidence 3.7-22.8 cases/million Female:male 5:1 Pulmonary fibrosis common, severe

More information

Disclosures. Scleroderma: Early Diagnosis How early is early? 10/28/2013. Difficult Scleroderma: How do I Approach this Patient?

Disclosures. Scleroderma: Early Diagnosis How early is early? 10/28/2013. Difficult Scleroderma: How do I Approach this Patient? Disclosures Financial support: None Difficult Scleroderma: How do I Approach this Patient? Francesco Boin, MD Assistant Professor of Medicine Director, Translational Research Johns Hopkins Scleroderma

More information

2/23/18. Disclosures. Rheumatic Diseases of Childhood. Making Room for Rheumatology. I have nothing to disclose. James J.

2/23/18. Disclosures. Rheumatic Diseases of Childhood. Making Room for Rheumatology. I have nothing to disclose. James J. Making Room for Rheumatology James J. Nocton, MD Disclosures I have nothing to disclose Rheumatic Diseases of Childhood Juvenile Idiopathic Arthritis (JIA) Systemic Lupus Erythematosus (SLE) Juvenile Dermatomyositis

More information

HYPERTENSIVE VASCULAR DISEASE

HYPERTENSIVE VASCULAR DISEASE HYPERTENSIVE VASCULAR DISEASE Cutoffs in diagnosing hypertension in clinical practice sustained diastolic pressures >90 mm Hg, or sustained systolic pressures >140 mm Hg Malignant hypertension A small

More information

MEDICAL SURGICAL NURSING II VNRS B85 ASSESSING CLIENTS WITH PERIPHERAL VASCULAR AND LYMPHATIC DISORDERS

MEDICAL SURGICAL NURSING II VNRS B85 ASSESSING CLIENTS WITH PERIPHERAL VASCULAR AND LYMPHATIC DISORDERS MEDICAL SURGICAL NURSING II VNRS B85 ASSESSING CLIENTS WITH PERIPHERAL VASCULAR AND INTRODUCTION: Clients with disorders of the peripheral vascular and lymphatic system experience a wide variety of circulatory

More information

SEVERE ORGAN INVOLVEMENT IN SYSTEMIC SCLEROSIS WITH DIFFUSE SCLERODERMA

SEVERE ORGAN INVOLVEMENT IN SYSTEMIC SCLEROSIS WITH DIFFUSE SCLERODERMA ARTHRITIS & RHEUMATISM Vol. 43, No. 11, November 2000, pp 2437 2444 2000, American College of Rheumatology 2437 SEVERE ORGAN INVOLVEMENT IN SYSTEMIC SCLEROSIS WITH DIFFUSE SCLERODERMA VIRGINIA D. STEEN

More information

Systemic Sclerosis. Scleroderma

Systemic Sclerosis. Scleroderma Systemic Sclerosis Scleroderma Definition Chronic systemic disorder Unknown etiology Thickening of the skin = scleroderma Involvement of multiple internal organs Early stage: inflammation Later stage:

More information

Sclérodermie systémique: Manifestations musculosquelettiques

Sclérodermie systémique: Manifestations musculosquelettiques Sclérodermie systémique: Manifestations musculosquelettiques Benjamin Chaigne Service de Médecine Interne, hôpital Cochin, Centre de Référence Vascularites nécrosantes et sclérodermie systémique Assistance

More information

Prevalence of pulmonary hypertension in systemic sclerosis and it s correlation with clinical variables

Prevalence of pulmonary hypertension in systemic sclerosis and it s correlation with clinical variables IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 9 Ver. X (September. 2017), PP 90-95 www.iosrjournals.org Prevalence of pulmonary hypertension

More information

AUTOIMMUNE DISORDERS IN THE ACUTE SETTING

AUTOIMMUNE DISORDERS IN THE ACUTE SETTING AUTOIMMUNE DISORDERS IN THE ACUTE SETTING Diagnosis and Treatment Goals Aimee Borazanci, MD BNI Neuroimmunology Objectives Give an update on the causes for admission, clinical features, and outcomes of

More information

LUPUS CAN DO EVERYTHING, BUT NOT EVERYTHING IS LUPUS LUPUS 101 SLE SUBSETS AUTOIMMUNE DISEASE 11/4/2013 HOWARD HAUPTMAN, MD IDIOPATHIC DISCOID LUPUS

LUPUS CAN DO EVERYTHING, BUT NOT EVERYTHING IS LUPUS LUPUS 101 SLE SUBSETS AUTOIMMUNE DISEASE 11/4/2013 HOWARD HAUPTMAN, MD IDIOPATHIC DISCOID LUPUS LUPUS 101 LUPUS CAN DO EVERYTHING, BUT NOT EVERYTHING IS LUPUS HOWARD HAUPTMAN, MD IDIOPATHIC DISCOID LUPUS SLE SUBSETS SUBACUTE CUTANEOUS LUPUS DRUG INDUCED LUPUS NEONATAL LUPUS LATE ONSET LUPUS ANTI-PHOSPHOLIPID

More information

Arthritis & Rheumatism

Arthritis & Rheumatism ARTHRITIS & RHEUMATISM Volume 37 Number 9, September 1994, pp 1265-1282 0 1994, American College of Rheumatology Arthritis & Rheumatism Official Journal of the American College of Rheumatology REVIEW GASTROINTESTINAL

More information

Blood Hyperviscosity / Plasmapheresis

Blood Hyperviscosity / Plasmapheresis Blood Hyperviscosity / Plasmapheresis In 1979, a research paper authored by Kahaleh, Sherer, and LeRoy titled Endothelial Injury in Scleroderma included the following passage: Many theories exist regarding

More information

Cigarette Smoking is not a Risk Factor for Systemic Sclerosis

Cigarette Smoking is not a Risk Factor for Systemic Sclerosis Brief Report Arthritis & Rheumatism DOI 10.1002/art.30492 Cigarette Smoking is not a Risk Factor for Systemic Sclerosis Authors: Prateek Chaudhary 1, Xing Chen 2, Shervin Assassi 1, Olga Gorlova 2, Hilda

More information

Atypical Neuroimaging Manifestations of Linear Scleroderma en coup de sabre

Atypical Neuroimaging Manifestations of Linear Scleroderma en coup de sabre Atypical Neuroimaging Manifestations of Linear Scleroderma en coup de sabre The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

More information

Functional vascular disorders

Functional vascular disorders Functional vascular disorders Raynaud s phenomenon Raynaud s phenomenon Refers to Intermittent,bilateral attacks of ischemia of the fingers or toes, and sometimes ears or nose. It clinically manifests

More information

Test Name Results Units Bio. Ref. Interval

Test Name Results Units Bio. Ref. Interval 135091660 Age 44 Years Gender Male 29/8/2017 120000AM 29/8/2017 100219AM 29/8/2017 105510AM Ref By Final EXTRACTABLENUCLEAR ANTIGENS (ENA), QUANTITATIVE ROFILE CENTROMERE ANTIBODY, SERUM 20-30 Weak ositive

More information

Dr Ian Roberts Oxford

Dr Ian Roberts Oxford Dr Ian Roberts Oxford Oxford Pathology Course 2010 for FRCPath Present the basic diagnostic features of the commonest conditions causing renal failure Highlight diagnostic pitfalls. Crescentic GN: renal

More information

Severe Fibrosis and Increased Expression of Fibrogenic Cytokines in the Gastric Wall of Systemic Sclerosis Patients

Severe Fibrosis and Increased Expression of Fibrogenic Cytokines in the Gastric Wall of Systemic Sclerosis Patients ARTHRITIS & RHEUMATISM Vol. 56, No. 10, October 2007, pp 3442 3447 DOI 10.1002/art.22940 2007, American College of Rheumatology Severe Fibrosis and Increased Expression of Fibrogenic Cytokines in the Gastric

More information

Thomas A. Medsger, Jr., MD University of Pittsburgh School of Medicine. Disclosures: None

Thomas A. Medsger, Jr., MD University of Pittsburgh School of Medicine. Disclosures: None Thomas A. Medsger, Jr., MD University of Pittsburgh School of Medicine Disclosures: None 4000+ patients enrolled 1972- present; 5+ visits per patient; 20,000+ patient years of follow- up All clinical and

More information

SCLERODERMA RENAL CRISIS. Presented by : Nouf Alanazi

SCLERODERMA RENAL CRISIS. Presented by : Nouf Alanazi SCLERODERMA RENAL CRISIS Presented by : Nouf Alanazi Agenda Prevalence Risk factors Pathology Diagnosis Prevention & monitoring Treatment Outcome & mortality. Summary & recommendations References SRC Abrupt

More information

Juvenile scleroderma: experience in one institution

Juvenile scleroderma: experience in one institution Original article Juvenile scleroderma: experience in one institution Chia-Yi Lo 1, Shyh-Dar Shyur 1, Szu-Hung Chu 1, Li-Hsin Huang 1, Yu-Hsuan Kao 1, Wei-Te Lei 1, Chieh- Han Cheng 1, Kuo-Hsi Lee 1, Chen-Kuan

More information

NIH Public Access Author Manuscript Arthritis Rheum. Author manuscript; available in PMC 2014 November 01.

NIH Public Access Author Manuscript Arthritis Rheum. Author manuscript; available in PMC 2014 November 01. NIH Public Access Author Manuscript Published in final edited form as: Arthritis Rheum. 2013 November ; 65(11): 2737 2747. doi:10.1002/art.38098. Classification Criteria for Systemic Sclerosis: An ACR-EULAR

More information

Megha M. Tollefson, MD Associate Professor of Dermatology and Pediatrics, Mayo Clinic Pediatric Morphea March 1, MFMER

Megha M. Tollefson, MD Associate Professor of Dermatology and Pediatrics, Mayo Clinic Pediatric Morphea March 1, MFMER Megha M. Tollefson, MD Associate Professor of Dermatology and Pediatrics, Mayo Clinic Pediatric Morphea March 1, 2019 2015 MFMER 3513105-1 Disclosures None 2015 MFMER 3513105-2 Topics to cover Classification

More information

Test Name Results Units Bio. Ref. Interval

Test Name Results Units Bio. Ref. Interval 135091662 Age 45 Years Gender Male 29/8/2017 120000AM 29/8/2017 100215AM 29/8/2017 110825AM Ref By Final RHEUMATOID AUTOIMMUNE COMREHENSIVE ANEL ANTI NUCLEAR ANTIBODY / FACTOR (ANA/ANF), SERUM ----- 20-60

More information

Test Name Results Units Bio. Ref. Interval

Test Name Results Units Bio. Ref. Interval LL - LL-ROHINI (NATIONAL REFERENCE 135091593 Age 25 Years Gender Male 30/8/2017 91600AM 30/8/2017 93946AM 31/8/2017 84826AM Ref By Final COLLAGEN DISEASES ANTIBODY ANEL ANTI NUCLEAR ANTIBODY / FACTOR (ANA/ANF),

More information

Artery 1 Head and Thoracic Arteries. Arrange the parts in the order blood flows through them.

Artery 1 Head and Thoracic Arteries. Arrange the parts in the order blood flows through them. Artery 1 Head and Thoracic Arteries 1. Given the following parts of the aorta: 1. abdominal aorta 2. aortic arch 3. ascending aorta 4. thoracic aorta Arrange the parts in the order blood flows through

More information

TRANSPARENCY COMMITTEE OPINION. 23 January 2008

TRANSPARENCY COMMITTEE OPINION. 23 January 2008 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 January 2008 TRACLEER 62.5 mg film-coated tablets Pack of 56 (CIP: 563 621-1) TRACLEER 125 mg film-coated tablets

More information

Cyramza. Cyramza (ramucirumab) Description. Section: Prescription Drugs Effective Date: October 1, 2014

Cyramza. Cyramza (ramucirumab) Description. Section: Prescription Drugs Effective Date: October 1, 2014 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cyramza Page: 1 of 5 Last Review Date: September 12, 2014 Cyramza Description Cyramza (ramucirumab)

More information

Definition Chronic autoimmune disease The body s immune system starts attacking itself Can affect most organs and tissues in the body Brain, lungs, he

Definition Chronic autoimmune disease The body s immune system starts attacking itself Can affect most organs and tissues in the body Brain, lungs, he LIVING WITH SYSTEMIC LUPUS ERYTHEMATOSUS Stacy Kennedy, M.D.,M.B.A. Rowan Diagnostic Clinic Salisbury, N.C. May 11, 2013 Agenda What is lupus Who is affected Causes of lupus Symptoms and organ involvement

More information

A clinical syndrome, composed mainly of:

A clinical syndrome, composed mainly of: Nephritic syndrome We will discuss: 1)Nephritic syndrome: -Acute postinfectious (poststreptococcal) GN -IgA nephropathy -Hereditary nephritis 2)Rapidly progressive GN (RPGN) A clinical syndrome, composed

More information

DRG Code DRG Description FY18 Average Charge

DRG Code DRG Description FY18 Average Charge DRG Code DRG Description FY18 Average Charge 3 ECMO OR TRACH W MV 96+ HRS OR PDX EXC FACE, MOUTH & NECK W MAJ O $ 665,511 4 TRACH W MV 96+ HRS OR PDX EXC FACE, MOUTH & NECK W/O MAJ O.R. $ 422,497 37 EXTRACRANIAL

More information

3 Circulatory Pathways

3 Circulatory Pathways 40 Chapter 3 Circulatory Pathways Systemic Arteries -Arteries carry blood away from the heart to the various organs of the body. -The aorta is the longest artery in the body; it branches to give rise to

More information

Scholars Journal of Medical Case Reports

Scholars Journal of Medical Case Reports Scholars Journal of Medical Case Reports Sch J Med Case Rep 2015; 3(9B):928-932 Scholars Academic and Scientific Publishers (SAS Publishers) (An International Publisher for Academic and Scientific Resources)

More information

Premium Specialty: Pediatrics

Premium Specialty: Pediatrics Premium Specialty: Pediatrics Credentialed Specialties include: Adolescent Medicine, Pediatric Adolescent, and Pediatrics This document is designed to be used in conjunction with the UnitedHealth Premium

More information

A number of factors point to the likelihood of a person with RA developing RV:

A number of factors point to the likelihood of a person with RA developing RV: What is rheumatoid vasculitis (RV)? Rheumatoid vasculitis (RV) is a rare but serious complication of rheumatoid arthritis (RA) an inflammatory disease that causes severe joint pain and damage, and can

More information

Regressive systemic sclerosis

Regressive systemic sclerosis Annals of the Rheumatic Diseases, 1986; 45, 384-388 Regressive systemic sclerosis CAROL BLACK, PAUL DIEPPE, TED HUSKISSON, AND FRANK DUDLEY HART From the Departments of Medicine and Rheumatology, West

More information

Secondary Raynaud s Phenomenon

Secondary Raynaud s Phenomenon Secondary Raynaud s Phenomenon Ulf Müller-Ladner University of Giessen Kerckhoff Clinic Bad Nauheim Germany Clinical problems in SSc Therapeutic solutions? Pulmonary fibrosis + PAH Diffuse Pulmonary fibrosis,

More information

PDF of Trial CTRI Website URL -

PDF of Trial CTRI Website URL - Clinical Trial Details (PDF Generation Date :- Fri, 09 Nov 2018 00:53:13 GMT) CTRI Number Last Modified On 30/07/2014 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study

More information

Summary of the risk management plan (RMP) for Kyprolis (carfilzomib)

Summary of the risk management plan (RMP) for Kyprolis (carfilzomib) EMA/639793/2015 Summary of the risk management plan (RMP) for Kyprolis (carfilzomib) This is a summary of the risk management plan (RMP) for Kyprolis, which details the measures to be taken in order to

More information

Tracheoesophageal Fistula and Esophageal Atresia

Tracheoesophageal Fistula and Esophageal Atresia Patient and Family Education Tracheoesophageal Fistula and Esophageal Atresia What is tracheoesophageal fistula? The word fistula means abnormal connection. Tracheoesophageal fistula (TEF) is a condition

More information

Long-Term (22 Year) Successful Treatment of Limited Systemic Scleroderma Using Plasmapheresis

Long-Term (22 Year) Successful Treatment of Limited Systemic Scleroderma Using Plasmapheresis Long-Term (22 Year) Successful Treatment of Limited Systemic Scleroderma Using Plasmapheresis Edward S. Harris MS, Herbert Meiselman ScD, Patrick M Moriarty MD, John Weiss MD PhD Abstract While a number

More information

ATHEROSCLEROSIS. Secondary changes are found in other coats of the vessel wall.

ATHEROSCLEROSIS. Secondary changes are found in other coats of the vessel wall. ATHEROSCLEROSIS Atherosclerosis Atherosclerosis is a disease process affecting the intima of the aorta and large and medium arteries, taking the form of focal thickening or plaques of fibrous tissue and

More information

Journal of Pediatric Sciences

Journal of Pediatric Sciences Journal of Pediatric Sciences Progressive facial hemiatrophy with contralateral maxillary mucocele Mohd Ashraf, Sheikh Javeed Sultan, Javed Ahmad Journal of Pediatric Sciences 2010;2:e11 How to cite this

More information

Non-commercial use only

Non-commercial use only Reumatismo, 2015; 67 (1): 21-25 Systemic sclerosis sine scleroderma: a of anterior uveitis T. Borges, J. Vilaça, S. Ferreira, I. Chora, S. Silva, C. Dias Internal Medicine Department, Centro Hospitalar

More information

Chronic Radiodermatitis Following Percutaneous Coronary Interventions

Chronic Radiodermatitis Following Percutaneous Coronary Interventions Chronic Radiodermatitis Following Percutaneous Coronary Interventions Jung-Yi Chan Chia-Yu Chu The incidence of radiodermatitis after percutaneous coronary interventions is rising with the increasing number

More information

Systemic sclerosis. Novel molecular and epidemiological features of disease.

Systemic sclerosis. Novel molecular and epidemiological features of disease. Systemic sclerosis. Novel molecular and epidemiological features of disease. Andréasson, Kristofer Published: 2013-01-01 Link to publication Citation for published version (APA): Andréasson, K. (2013).

More information

Stem Cell Transplantation (SCT) in Scleroderma

Stem Cell Transplantation (SCT) in Scleroderma Stem Cell Transplantation (SCT) in Scleroderma Yes or No? Philippe Guilpain, MD, PhD Department of Internal Medicine- Multiorganic diseases Competence center for auto-immune diseases Saint Eloi Hospital,

More information

Human Body Systems. Human Body Project Notes

Human Body Systems. Human Body Project Notes Human Body Systems Human Body Project Notes Human Body Organ Systems for the Project Big Idea: Organ systems are composed of organs that are made of more than one type of tissue. Tissues are made of one

More information

Scleroderma renal crisis following silicone breast implant rupture: a case report and review of the literature

Scleroderma renal crisis following silicone breast implant rupture: a case report and review of the literature CASE REPORT Clinical and Experimental Rheumatology 2014; 32: 262-266. Scleroderma renal crisis following silicone breast implant rupture: a case report and review of the literature G. Al Aranji¹, D. White¹,

More information

Incidental Esophageal Findings on Chest CT. Amira Hussien, MD, Elliot Fishman, MD, Bouchra Younes, MD, Ahmed Hatw. Johns Hopkins Medical Institution

Incidental Esophageal Findings on Chest CT. Amira Hussien, MD, Elliot Fishman, MD, Bouchra Younes, MD, Ahmed Hatw. Johns Hopkins Medical Institution Incidental Esophageal Findings on Chest CT Amira Hussien, MD, Elliot Fishman, MD, ouchra Younes, MD, Ahmed Hatw. Johns Hopkins Medical Institution I have nothing to disclose. DISCLOSURE INTRODUCTION Although

More information

BMI ( ) kg / m 2 (P < 0.001) OSAS ( ) ( ) cm P < OSAS OSAS

BMI ( ) kg / m 2 (P < 0.001) OSAS ( ) ( ) cm P < OSAS OSAS CHEST Luca Busetto, MD; Giuliano Enzi, MD; Emine Meral Inelmen, MD; Gabriella Costa, MD; Valentina Negrin, MD; Giuseppe Sergi, MD; and Andrea Vianello, MD (OSAS) OSAS 17 OSAS (BMI) (55.8 9.9) kg / m 2

More information

APR-DRG Description Ave Charge

APR-DRG Description Ave Charge Abdominal Pain 16,500.25 2.8 6,000.09 Acute & Subacute Endocarditis 15,339.30 3.0 5,113.10 Acute Myocardial Infarction 17,687.46 2.6 6,802.87 Alcohol Abuse & Dependence 19,126.64 4.2 4,553.96 Alcoholic

More information

Introduction. Results. Discussion. Histopathologic and immunohistochemical findings. Results. conclusions,

Introduction. Results. Discussion. Histopathologic and immunohistochemical findings. Results. conclusions, 1/5 2/5 Carcinoma distinctive carcinoma. form erysipeloides (CE), metastasis. which clinically Itfrom has resembles been termed erysipelas, is an uncommon, but may extend It164 toclassically back, presents

More information